Board of Directors

Luke Evnin, Ph.D. - Potenza Chairman, and Co-founder and Managing Director of MPM Capital

Luke Evnin, Ph.D. is Co-founder and Manging Director of MPM Capital. He co-founded MPM with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they lead has been the inspiration and driving force in building companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis:NVS), Epizyme (EPZM), Idenix (acquired by Merck:MRK), Pacira (PCRX), Pharmasset (acquired by Gilead:GILD) and Radius (RDUS). Prior to co-founding MPM, he was a General Partner at the venture capital firm Accel Partners. He has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. Dr. Evnin also devotes his time to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, the External Advisory Boards for QB3, and the Mission Bay Capital Fund at UCSF. He received his Ph.D. in biochemistry from the University of California, San Francisco. View Profile

Dan J. Hicklin, Ph.D. - Potenza President and Chief Executive Officer

Dan Hicklin, Ph.D. is President and Chief Executive Officer at Potenza Therapeutics. He brings over 25 years of biopharmaceutical research and operations experience with particular expertise in oncology drug development. Dr. Hicklin co-founded Potenza in 2014. He has served as a Managing Director at the life sciences venture capital investment firm MPM Capital since 2014 and is also President of Trieza Therapeutics and a board member of Tizona Therapeutics, Harpoon Therapeutics, Maverick Therapeutics and the Scientific Advisory Board of Oncorus Therapeutics. Previously, Dr. Hicklin served as President and Chief Scientific Officer of CoStim Pharmaceuticals, which was acquired by Novartis in 2014. From 2007 to 2013, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston where he oversaw a number of immunotherapy projects including the development of Keytruda® (pembrolizumab). Dr. Hicklin began his career at ImClone Systems where he held several positions of increasing responsibility from 1987-2007, most recently as Vice President of Experimental Therapeutics. Dr. Hicklin’s team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), and other cancer therapies that were acquired by Eli Lilly in 2008. Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his M.S. and Ph.D. in microbiology & immunology from New York Medical College and earned his B.S. from the University of Iowa. View Profile

Arnold Oronsky, Ph.D. - General Partner of InterWest Partners

Arnold Oronsky is General Partner of InterWest Partners. In addition to his responsibilities at InterWest, he also serves as a senior lecturer at the Department of Medicine at Johns Hopkins Medical School. Prior to joining InterWest’s healthcare investing team full-time in 1994, Dr. Oronsky was Vice President of Discovery Research at the Lederle Laboratories division of American Cyanamid Company where he directed research for new drugs. Dr. Oronsky has published more than 160 articles in scientific journals and received a Ph.D. in immunology from Columbia University. View Profile

Shunichiro Matsumoto, Ph.D. - Vice President of Astellas Innovation Management (AIM)

Shunichiro Matsumoto, Ph.D. is Senior Vice President of Innovation & Incubation Research Labs., Drug Discovery Research at Astellas Pharma Inc., based in Tsukuba, Japan, and President of Astellas Venture Management LLC, located in Menlo Park, CA, USA. Prior to his current role, he served as Senior Director of Product and Portfolio Strategy at Astellas Pharma Inc. He has 5 years of experience in venture capital, including serving as Investment Director at Astellas Venture Management LLC and 14 years of experience in R&D, specializing in molecular biology at Astellas Pharma Inc. and the former Yamanouchi Pharmaceutical Co., Ltd. Dr. Matsumoto received his Ph.D. in medicine from the University of Tsukuba, an M.Sc. in agriculture from Kyoto University, and an MBA from McGill University.